Helmholtz Munich, one of Ascenion’s long-standing partners, will coordinate the AiChemist project, starting in September 2023. The goal is to develop representation learning approaches that can support drug discovery by predicting the most decisive properties of drug candidates based on their chemical structures, such as toxicity, activity, and optimal synthetic routes. The models will be thoroughly benchmarked with regards to accuracy and explainability - parameters that are crucial for evaluation, confidence, and responsible use of results. Fellows of the AiChemist program will closely cooperate with industry partners and will benefit from a highly structured and comprehensive curriculum delivered through regular online courses and schools. As an associated partner, Ascenion will provide tailored seminars to raise the researchers’ awareness for IP-relevant aspects of their work.
AiChemist is funded by the European Union’s Horizon research and innovation program as part of the Marie Skłodowska-Curie Actions Doctoral Networks (MSCA-DN).
Further information:
AIChemist-Website